Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.

Huaie LiuWeilin ZengPallavi MallaChengqi WangSeetha LakshmiKami KimLynette MenezesZhaoqing YangLiwang Cui

Published in: Infection (2022)

The standard 14-day primaquine regimen carries a significant risk of acute hemolytic anemia (AHA) in vivax patients without G6PD testing in a population with a high prevalence of G6PD deficiency and anemia. G6PD testing would avoid most of the clinically significant Hb reductions and AHA in male patients.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes
acute respiratory distress syndrome
patient reported
aortic dissection